Previous studies demonstrate that TETA could overcome cisplatin resistance in human ovarian cancer cell cultures, via inhibition of Cu/Zn superoxide dismutase, namely, SOD1 [16, 17]. This evidence concerns the gene SOD1 and ovarian carcinoma.